ANXA2
ATC code L01
Abagovomab
Abemaciclib
Abituzumab
Acalabrutinib
Actifed
Adagrasib
Adecatumumab
Adipotide
Afatinib
Aflibercept
Alectinib
Alemtuzumab
Allen & Hanburys
Alpelisib
Amatuximab
American Society of Health-System Pharmacists
Amivantamab
Amoxicillin/clavulanic acid
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anatumomab mafenatox
Andrew Witty
Antigen
Antineoplastic
Antineoplastic agent
Aquafresh
Asciminib
Ascrinvacumab
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
B-cell maturation antigen
BC Powder
BRAF (gene)
Balstilimab
Baricitinib
Bavituximab
Bcr-abl fusion protein
Beclometasone
Bectumomab
Beecham Group
Belantamab mafodotin (data page)
Bermekimab
Bevacizumab
Bexsero
Binimetinib
Biotene
Bivatuzumab mertansine
Blinatumomab
Block Drug
Boostrix
Bosutinib
Botensilimab
Boxed warning
Breakthrough therapy
Brentuximab vedotin
Brigatinib
Brontictuzumab
Bruton's tyrosine kinase
Bupropion
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD38
CD3 (immunology)
CD52
CDK inhibitor
Cabozantinib
Caltrate
Canada v. GlaxoSmithKline Inc.
Cancer immunotherapy
Cantuzumab mertansine
Cantuzumab ravtansine
Capmatinib
Carotuximab
Catumaxomab
Cediranib
Cemiplimab
Centrum (multivitamin)
Ceritinib
Cervarix
Cetuximab
ChapStick
Chemical formula
Chimeric antibody
Chris Gent
Christopher v. SmithKline Beecham Corp.
Cimetidine
Cirmtuzumab
Citatuzumab bogatox
Cixutumumab
ClinicalTrials.gov
Clinical trial
Cobimetinib
Cofetuzumab pelidotin
Conatumumab
Copanlisib
Cosibelimab
Crizotinib
Dabrafenib
Dacetuzumab
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Daratumumab
Dasatinib
Demcizumab
Denileukin diftitox
Denintuzumab mafodotin
Depatuxizumab mafodotin
Detumomab
Dinutuximab
Dinutuximab beta
Doi (identifier)
Dostarlimab
Drozitumab
DrugBank
Drug Industry Documents Archive
Drug class
Drug nomenclature
Drugs.com
Duligotumab
Durvalumab
Dusigitumab
Duvelisib
Duvortuxizumab
EML4
Ecromeximab
Edrecolomab
Elotuzumab
Elranatamab
Emactuzumab
Emergen-C
Emibetuzumab
Emma Walmsley
Encorafenib
Enfortumab vedotin
Engerix-B
Eno (drug)
Enoblituzumab
Enoticumab
Ensituximab
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlotinib
Ertumaxomab
Etaracizumab
European Medicines Agency
Everolimus
Excedrin (brand)
Exotoxin
FDA
Farletuzumab
Fedratinib
Fibroblast growth factor receptor
Ficlatuzumab
Figitumumab
Filgotinib
First-in-class medication
Flanvotumab
Flotetuzumab
FluLaval
Fluarix
Fluticasone/salmeterol
Fluticasone propionate
Food and Drug Administration
Fruquintinib
Fusion protein
Futibatinib
Futuximab
GSK plc
Ganitumab
Gefitinib
Gemtuzumab ozogamicin
Geritol
Gilteritinib
Girentuximab
Glasdegib
GlaxoSmithKline Pakistan
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Prize
GlaxoSmithKline Services Unlimited v Commission
Glembatumumab vedotin
Glofitamab
Goody's Powder
H5N1 vaccine
HER2/neu
Haleon
Havrix
Hdl (identifier)
Hedgehog signaling pathway
Henry Wellcome
Hepatitis A and B vaccine
Hepatyrix
Hiberix
Horlicks
Human Genome Sciences
Humanized
Humanized antibody
Ibandronic acid
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Inavolisib
Indatuximab ravtansine
Indium (111In) altumomab pentetate
Indium (111In) capromab pendetide
Indium (111In) igovomab
Indium (111In) satumomab pendetide
Infanrix
Infigratinib
Inotuzumab ozogamicin
Interleukin 2
International nonproprietary name
Intetumumab
Intravenous therapy
Iodine (131 I) derlotuximab biotin
Ipilimumab
Iratumumab
Isatuximab
Istiratumab
Janus kinase
John K. Smith
Judy Lewent
KEGG
KRAS
Kinrix
Labetuzumab
Lamotrigine
Lapatinib
Larotrectinib
Laurie Glimcher
Lazertinib
Lenvatinib
Lestaurtinib
Leukemia
Lexatumumab
Lifastuzumab vedotin
Lilotomab
Lintuzumab
List of GSK plc products
List of withdrawn drugs
Loncastuximab tesirine
Lorlatinib
Lorvotuzumab mertansine
Lucatumumab
Lucozade
Lumretuzumab
Lymphatic system
Lymphoma
Lynn Elsenhans
M. S. Banga
MEN1
MTOR inhibitor
Mahlon Kline
Mapatumumab
Margetuximab
Masitinib
Matuzumab
Menveo
Midostaurin
Milatuzumab
Minretumomab
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mitumomab
Mobocertinib
Mogamulizumab
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Monomethyl auristatin F
Mosunetuzumab
Moxetumomab pasudotox
Multiple myeloma
Myeloid
Nacolomab tafenatox
Naptumomab estafenatox
Narnatumab
Naxitamab
Necitumumab
Neoplasm
Neratinib
Nesvacumab
Nicoderm
Nicorette
Nilotinib
Nimotuzumab
Nintedanib
Niquitin
Nivolumab
Non-receptor tyrosine kinase
Obinutuzumab
Ocaratuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Onartuzumab
Ontuxizumab
Oportuzumab monatox
Oregovomab
Orelabrutinib
Orlistat
Orphan drug
Osimertinib
Otlertuzumab
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Pandemrix
Panitumumab
Parodontax
Paroxetine
Parsaclisib
Parsatuzumab
Patrick Vallance
Patritumab
Pazopanib
Pediarix
Pembrolizumab
Pemigatinib
Pemtumomab
Pertuzumab
Pexidartinib
Phases of clinical research
Philip Hampton
Pi3K inhibitor
Piboserod
Pinatuzumab vedotin
Pirtobrutinib
Platelet-derived growth factor receptor
Polatuzumab vedotin
Ponatinib
Pralsetinib
Priority review
Pritumumab
Proapoptotic
Prohibitin
Prolgolimab
Proteasome inhibitor
Public domain
Quizartinib
RET proto-oncogene
RTK class III
Rabavert
Racotumomab
Radotinib
Radretumab
Ramucirumab
Ranitidine
Receptor tyrosine kinase
Recherche et Industrie Th√©rapeutiques
Regorafenib
Regulation of therapeutic goods
Reliant Pharmaceuticals
Repotrectinib
Respiratory syncytial virus vaccine
Retifanlimab
Revumenib
Ribena
Ribociclib
Ridaforolimus
Rilotumumab
Ripretinib
Rituximab
Robatumumab
Rociletinib
Rosiglitazone
Rosmantuzumab
Rotarix
Route of administration
Rovalpituzumab tesirine
Roy M. Anderson
Ruxolitinib
S. E. Massengill Company
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Salbutamol
Selpercatinib
Selumetinib
Semaxanib
Sensodyne
Seribantumab
Serplulimab
Sibrotuzumab
Side Effects (Bass book)
Silas M. Burroughs (pharmacist)
Siltuximab
Simon Dingemans
Simtuzumab
Sirolimus
Smith, Kline & French
Sofituzumab vedotin
Solitomab
Sonidegib
Sorafenib
Sotorasib
Src (gene)
Stiefel Laboratories
Study 329
Sugemalimab
Sunitinib
Tafasitamab
Talquetamab
Taplitumomab paptox
Tarextumab
Targeted cancer therapy
Tarlatamab
Tebentafusp
Technetium (99mTc) arcitumomab
Technetium (99mTc) nofetumomab merpentan
Technetium (99mTc) pintumomab
Technetium (99mTc) votumumab
Teclistamab
Temsirolimus
Tenatumomab
Tepotinib
Teprotumumab
Tesaro
Thomas Beecham (chemist)
Tigatuzumab
Tislelizumab
Tisotumab vedotin
Tivozanib
Toceranib
Topotecan
Toripalimab
Tositumomab
Tovetumab
Trametinib
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trifunctional antibody
Trilaciclib
Tucatinib
Tucotuzumab celmoleukin
Tums
Tyrosine kinase inhibitor
Ublituximab
Unique Ingredient Identifier
United States v. GlaxoSmithKline
United States v. Glaxo Group Ltd.
Urs Rohner
VEGF receptors
Vandetanib
Vandortuzumab vedotin
Vantictumab
Vanucizumab
Vascular endothelial growth factor
Vascular endothelial growth factor A
Veltuzumab
Vemurafenib
Venetoclax
ViiV Healthcare
Vismodegib
Vivienne Cox
Vorsetuzumab mafodotin
WHO Model List of Essential Medicines
Yttrium (90Y) clivatuzumab tetraxetan
Yttrium (90Y) tacatuzumab tetraxetan
Zalutumumab
Zanidatamab
Zanubrutinib
Zenocutuzumab
Zolbetuximab
Zoster vaccine